GlassScriptPhysician profile
Philip L Berman
NPI 1891835195
$43,507.79
in general payments reported to CMS, 2019-2025
48 companies · $3,189 in 2025
The $3,189 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,396 · 2020: $9,223 · 2021: $14K · 2022: $6,327 · 2023: $3,336 · 2024: $4,811 · 2025: $3,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,634 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,350 · Travel and Lodging: $326 · Entertainment: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,634.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,350.00 |
| Travel and Lodging | $325.76 |
| Entertainment | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,744.73 | 2019-2025 | Farxiga, Wainua |
| Cvrx, INC. | $3,009.44 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $2,349.31 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,833.47 | 2019-2025 | |
| Amgen INC. | $1,415.06 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,041.72 | 2019-2025 | Ensite, Mitraclip, Ensite Precision |
| Boston Scientific Corporation | $980.87 | 2019-2025 | Avvigo Guidance System, Ilab Ultrasound Imaging System, Emerge Push |
| Boehringer Ingelheim Pharmaceuticals, INC. | $963.09 | 2019-2025 | Jardiance |
| Medtronic, INC. | $767.22 | 2021-2025 | Symplicity G3, Micra, Linq II |
| Shockwave Medical, INC | $710.49 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $696.22 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $543.72 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $524.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $516.17 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $314.67 | 2022-2024 | Optimizer |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.